Abbott reported strong financial results for the fourth quarter and full-year 2024, with total sales for the year reaching $42.0 billion, a 4.6% increase compared to 2023. Organic sales growth for the underlying base business was 9.6%, excluding COVID-19 testing-related sales. For Q4 2024, sales totaled $11.0 billion, a 7.2% increase, with organic growth excluding COVID-19 tests at 10.1%.

Abbott achieved a full-year GAAP diluted EPS of $7.64 and adjusted EPS of $4.67, with significant contributions from its medical devices and nutrition segments. Key growth drivers included the strong performance of products like FreeStyle Libre® and Ensure®. Abbott also made significant advancements in its R&D pipeline, launching over 15 new products or indications.

For 2025, Abbott forecasts organic sales growth of 7.5% to 8.5%, an adjusted operating margin of 23.5% to 24.0%, and adjusted EPS between $5.05 and $5.25. Additionally, Abbott declared its 404th consecutive quarterly dividend, reflecting its strong commitment to shareholder returns.